Moderna And Merck Celebrate Success With Cancer Vaccine In Phase 3 Study
Stocks
Moderna And Merck Celebrate Success With Cancer Vaccine In Phase 3 Study
A personalized mRNA vaccine from Moderna and Merck has been shown in a crucial Phase 3 study to keep melanoma patients cancer-free longer after surgical removal of the tumor.
2 min read
Wouter De Clerck
- aandelen
- biotech
- Farmacie
- Fase 3 Studie
- Gezondheidszorg
- Kankervaccin
- Melanoom
- Merck
- Moderna
- mRNA
Written by
Wouter De Clerck
Economics Editor · Leuven (BE)
Wouter follows macroeconomics, interest rate policy, and precious metals. He connects central bank decisions with what happens in the crypto and gold markets.